Abstract
Inhibitors of thymidylate synthase (TS) play an essential role in the pharmacological management of several tumors. Two antifolates, Raltitrexed and Pemetrexed, are licensed anticancer drugs, with Pemetrexed, unlike Raltitrexed, undergoing further intense clinical development. Other antifolate TS inhibitors, recently/currently tested in clinical studies, that show encouraging anticancer activities are Plevitrexed, GW7904L and Nolatrexed. A new prospect among antifolates, demonstrating a very desirable pattern of pharmacological properties, is BGC 945 that showed promising antitumor activities and has been nominated for clinical development. In this paper, apart from reviewing their biochemical and pharmacological properties, up-to-date characteristics of clinical development of all the mentioned agents are presented. In addition, trends and perspectives for developing improved antifolate inhibitors of TS and future drugs are discussed. Drug resistance is the main barrier to more effective treatment of cancers with antifolates; therefore, mechanisms of antifolate resistance and currently applied approaches to overcome it are also pointed out in the review.
Keywords: Thymidylate synthase (TS), inhibitors, antifolates, anticancer drugs, Thymidylate synthase, TS ThyA, deoxyuridylate, dUMP, 5,10-methylene-5,6,7,8-tetrahydrofolate, mTHF, thymidylate, dTMP, 7,8-dihydrofolate, DHF, 5-fluorouracil, FUra, 5-fluoro-2'-deoxyuridylate, (FdUMP), N(4)-hydroxy-dCMP, 5-fluoro congener, N(4)-OH-FdCMP, Raltitrexed, CB3717, PDDF, antifolate analogue, phase III Pan European Trial in Adjuvant Colon Cancer-1 (PETACC-1), malig-nant pleural mesothelioma, Pemetrexed, ALIMTA, MTA, LY231514, antifolate, dihydrofolate re-ductase, DHFR, aminoimidazole carboxamide ribonu-cleotide formyltransferase, Aicarft, lometrexol, PLEVITREXED, GW1843, NOLATREXED, BGC 945
Mini-Reviews in Medicinal Chemistry
Title: Antifolate Inhibitors of Thymidylate Synthase as Anticancer Drugs
Volume: 10 Issue: 13
Author(s): A. Jarmula
Affiliation:
Keywords: Thymidylate synthase (TS), inhibitors, antifolates, anticancer drugs, Thymidylate synthase, TS ThyA, deoxyuridylate, dUMP, 5,10-methylene-5,6,7,8-tetrahydrofolate, mTHF, thymidylate, dTMP, 7,8-dihydrofolate, DHF, 5-fluorouracil, FUra, 5-fluoro-2'-deoxyuridylate, (FdUMP), N(4)-hydroxy-dCMP, 5-fluoro congener, N(4)-OH-FdCMP, Raltitrexed, CB3717, PDDF, antifolate analogue, phase III Pan European Trial in Adjuvant Colon Cancer-1 (PETACC-1), malig-nant pleural mesothelioma, Pemetrexed, ALIMTA, MTA, LY231514, antifolate, dihydrofolate re-ductase, DHFR, aminoimidazole carboxamide ribonu-cleotide formyltransferase, Aicarft, lometrexol, PLEVITREXED, GW1843, NOLATREXED, BGC 945
Abstract: Inhibitors of thymidylate synthase (TS) play an essential role in the pharmacological management of several tumors. Two antifolates, Raltitrexed and Pemetrexed, are licensed anticancer drugs, with Pemetrexed, unlike Raltitrexed, undergoing further intense clinical development. Other antifolate TS inhibitors, recently/currently tested in clinical studies, that show encouraging anticancer activities are Plevitrexed, GW7904L and Nolatrexed. A new prospect among antifolates, demonstrating a very desirable pattern of pharmacological properties, is BGC 945 that showed promising antitumor activities and has been nominated for clinical development. In this paper, apart from reviewing their biochemical and pharmacological properties, up-to-date characteristics of clinical development of all the mentioned agents are presented. In addition, trends and perspectives for developing improved antifolate inhibitors of TS and future drugs are discussed. Drug resistance is the main barrier to more effective treatment of cancers with antifolates; therefore, mechanisms of antifolate resistance and currently applied approaches to overcome it are also pointed out in the review.
Export Options
About this article
Cite this article as:
Jarmula A., Antifolate Inhibitors of Thymidylate Synthase as Anticancer Drugs, Mini-Reviews in Medicinal Chemistry 2010; 10 (13) . https://dx.doi.org/10.2174/13895575110091211
DOI https://dx.doi.org/10.2174/13895575110091211 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
Call for Papers in Thematic Issues
Bioprospecting of Natural Products as Sources of New Multitarget Therapies
According to the Convention on Biological Diversity, bioprospecting is the exploration of biodiversity and indigenous knowledge to develop commercially valuable products for pharmaceutical and other applications. Bioprospecting involves searching for useful organic compounds in plants, fungi, marine organisms, and microorganisms. Natural products traditionally constituted the primary source of more than ...read more
Computational Frontiers in Medicinal Chemistry
The thematic issue "Computational Frontiers in Medicinal Chemistry" provides a robust platform for delving into state-of-the-art computational methodologies and technologies that significantly propel advancements in medicinal chemistry. This edition seeks to amalgamate top-tier reviews spotlighting the latest trends and breakthroughs in the fusion of computational approaches, including artificial intelligence (AI) ...read more
Natural Products and Dietary Supplements in Alleviation of Metabolic, Cardiovascular, and Neurological Disorders
Metabolic disorders like diabetes, obesity, inflammation, oxidative stress, cancer etc, cardiovascular disorders like angina, myocardial infarction, congestive heart failure etc as well as neurological disorders like Alzheimer?s, Parkinson?s, Epilepsy, Depression, etc are the global burden. They covered the major segment of the diseases and disorders from which the human community ...read more
Natural Products in Drug Discovery
Natural products have always been one of the important ways of drug discovery due to their novel skeleton and diverse functional group characteristics. According to statistics, between 1981 and 2019, the FDA approved a total of 1,394 small molecule drugs for marketing, of which 930 marketed drugs originated from the ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cytotoxicity of Novel Sulfanilamides Towards Sensitive and Multidrugresistant Leukemia Cells
Current Medicinal Chemistry Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors from the Natural Origin: A Recent Perspective
Anti-Cancer Agents in Medicinal Chemistry Indoleamine 2,3-dioxygenase (IDO): Biology and Target in Cancer Immunotherapies
Current Cancer Drug Targets The Roles of Parathyroid Hormone and Calcitonin in Bone Remodeling: Prospects for Novel Therapeutics
Endocrine, Metabolic & Immune Disorders - Drug Targets Astatine Radiopharmaceuticals: Prospects and Problems
Current Radiopharmaceuticals Ent-11α-Hydroxy-15-Oxo-Kaur-16-en-19-Oic-Acid Induces Apoptosis of Human Malignant Cancer Cells
Current Drug Targets Cigarette Smoking, Metabolic Activation and Carcinogenesis
Current Drug Metabolism New Approaches to Target the Androgen Receptor and STAT3 for Prostate Cancer Treatments
Mini-Reviews in Medicinal Chemistry Molecular Targeting of Acid Ceramidase: Implications to Cancer Therapy
Current Drug Targets Evaluation of the Ability of an Organic Derivative of Ruthenium(II) to Reinforce the Cytotoxicity of Fast Neutron Against Malignant Cells in Culture
Letters in Drug Design & Discovery Development and Current Status of Unconventional Platinum Anticancer Complexes
Mini-Reviews in Medicinal Chemistry The Therapeutic Target Hsp90 and Cancer Hallmarks
Current Pharmaceutical Design Targeted Therapies in Combination with Radiotherapy in Oesophageal and Gastroesophageal Carcinoma
Current Medicinal Chemistry Automated PET Radiotracer Manufacture on the BG75 System and Imaging Validation Studies of [18F]fluoromisonidazole ([18F]FMISO)
Current Radiopharmaceuticals Evaluation of Osteoporosis Risk Associated with Chronic Use of Morphine, Fentanyl and Tramadol in Adult Female Rats
Current Drug Safety Proteostasis, an Emerging Therapeutic Paradigm for Managing Inflammatory Airway Stress Disease
Current Molecular Medicine Advances in Gene Therapy for Bladder Cancer
Current Gene Therapy Clinical Analysis Methods of Voice Disorders
Current Bioinformatics Chemoradiation for Oropharyngeal Carcinoma for Organ Preservation
Current Cancer Therapy Reviews Therapeutic Implications of Tocilizumab, A Humanized Anti-Interleukin-6 Receptor Antibody, for Various Immune-Mediated Diseases: An Update Review
Current Rheumatology Reviews